GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...
A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some ...
LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...
GSK is now looking to start a phase 3 trial in the first-line setting shortly, Abdullah said. The DREAMM-10 study will once again pit Blenrep against Darzalex, this time as part of front-line ...
Ben Hargreaves examines the reasons supplied by the survey and why GSK is invested in the answers. The emergence of COVID-19 meant that public awareness around vaccination and its importance in ...
GSK’sGSK-0.34%decrease; red down pointing triangle blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return to ...
incorporated in the year 1924, is a Large Cap company (having a market cap of Rs 38,541.57 Crore) operating in Pharmaceuticals sector. GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue ...
Arexvy is an RSV vaccine currently authorised in the US and a further 35 countries. Credit: MargJohnsonVA/Shutterstock. GlaxoSmithKline (GSK) has received approval ...